MIB-1 labelling index is an independent prognostic marker in primary breast cancer.
The proliferative activity of a tumour is considered to be an important prognostic factor in primary breast cancer. We have investigated the prognostic value of the MIB-1 labelling index in 341 patients with primary breast cancer and compared the results with the S-phase fraction in 220 patients of the same cohort. All patients were treated in one hospital and had a median follow-up of 128 months. No correlation between MIB-1 labelling and S-phase fraction could be demonstrated. MIB-1 had prognostic value for disease-free survival in the whole group of patients (P < 0.001) and in the node-negative subgroup (P < 0.001). In multivariate analysis, MIB-1 was an independent prognostic factor (P = 0.004) besides axillary lymph node status (P = 0.001). In univariate analysis high S-phase fraction was associated with decreased overall survival (P = 0.04); however, not in multivariate analysis. Moreover, S-phase fraction had a borderline prognostic significance for post-relapse survival in multivariate analysis (P= 0.08). Thus, in conclusion, the growth fraction of a tumour as determined by the MIB-1 labelling index is an important prognostic factor in patients with primary breast cancer.
Department of Internal Medicine, University Hospital Maastricht, The Netherlands.
R L
RL
Jansen
P S
PS
Hupperets
J W
JW
Arends
S R
SR
Joosten-Achjanie
A
A
Volovics
H C
HC
Schouten
H F
HF
Hillen
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000032:analysis*; D001943:Breast Neoplasms / Q000175:diagnosis*; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000276:immunology*; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016196:S Phase
D000911:Antibodies, Monoclonal; D019394:Ki-67 Antigen